0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non–Small Cell Lung Cancer

Kai-Lung Chen, MD1; Chia-Chi Lin, MD, PhD2,3; Yung-Tsu Cho, MD1; Che-Wen Yang, MD1; Yi-Shuan Sheen, MD1; Hsiao-En Tsai, MD4; Chia-Yu Chu, MD, PhD1
[+] Author Affiliations
1Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei
2Department of Oncology, National Taiwan University Hospital, Taipei
3Department of Urology, National Taiwan University College of Medicine, Taipei
4Department of Surgery, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu City
JAMA Dermatol. 2016;152(3):340-342. doi:10.1001/jamadermatol.2015.4448.
Text Size: A A A
Published online

Extract

This study compares the incidences and severities of 4 types of skin toxic effects for 3 different epidermal growth factor receptor tyrosine kinase inhibitors in the same patient cohort.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used to treat non–small cell lung cancer. Four major skin toxic effects with different incidences have been reported from clinical studies, including acneiform eruption (60%-94%), pruritus (16%-60%), xerosis (4%-38%), and paronychia (6%-12%).1,2 However, a direct comparison of the incidences and severities of the 4 types of skin toxic effects for 3 different EGFR-TKIs in the same patient cohort has been lacking to date.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.
Study Design and Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib Hydrochloride, or Afatinib Treatment

A and B, Study design and patient enrollment. C-E, Comparison of the incidence of 4 major skin toxic effects. F, Comparison of the total dermatologic visits for any kind of skin toxicity within the first 180 days of drug exposure. A indicates afatinib; E, erlotinib; EA, erlotinib-afatinib; EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors; G, gefitinib; GA, gefitinib-afatinib; GE, gefitinib-erlotinib, GEA, gefitinib-erlotinib-afatinib.

aP < .05.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

945 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs
brightcove.createExperiences();